Last reviewed · How we verify
Advil PM Liqui-Gels
Ibuprofen is a non-selective COX-2 inhibitor.
Ibuprofen is a non-selective COX-2 inhibitor. Used for Relief of mild to moderate pain, Reduction of inflammation.
At a glance
| Generic name | Advil PM Liqui-Gels |
|---|---|
| Sponsor | HALEON |
| Drug class | NSAID |
| Target | COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 1 |
Mechanism of action
Ibuprofen works by inhibiting the enzyme cyclooxygenase-2 (COX-2), which is involved in the production of prostaglandins, leading to pain relief and reduced inflammation.
Approved indications
- Relief of mild to moderate pain
- Reduction of inflammation
Common side effects
- Gastrointestinal upset
- Headache
- Dizziness
Key clinical trials
- A Bioequivalence Study of Advil PM Liqui-Gels Minis (Ibuprofen/Diphenhydramine Hydrochloride 200 mg/25 mg) Compared to the Current Marketed Advil PM Liqui-Gels (Ibuprofen/Diphenhydramine Hydrochloride 200 mg/25 mg) in Healthy Adult Subjects Under Fasted Conditions (PHASE1)
- Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine (PHASE4)
- Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets Under Fed Condition (PHASE1)
- Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets Under Fasting Condition (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Advil PM Liqui-Gels CI brief — competitive landscape report
- Advil PM Liqui-Gels updates RSS · CI watch RSS
- HALEON portfolio CI